AU2012359081B2 - Combination therapy with interferon and andrographolides for multiple sclerosis - Google Patents

Combination therapy with interferon and andrographolides for multiple sclerosis Download PDF

Info

Publication number
AU2012359081B2
AU2012359081B2 AU2012359081A AU2012359081A AU2012359081B2 AU 2012359081 B2 AU2012359081 B2 AU 2012359081B2 AU 2012359081 A AU2012359081 A AU 2012359081A AU 2012359081 A AU2012359081 A AU 2012359081A AU 2012359081 B2 AU2012359081 B2 AU 2012359081B2
Authority
AU
Australia
Prior art keywords
group
interferon
formula
compound
andrographolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012359081A
Other languages
English (en)
Other versions
AU2012359081A1 (en
Inventor
Rafael Burgos
Juan L. Hancke Orozco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INNOBIOSCIENCE LLC
Original Assignee
INNOBIOSCIENCE LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012359081(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by INNOBIOSCIENCE LLC filed Critical INNOBIOSCIENCE LLC
Publication of AU2012359081A1 publication Critical patent/AU2012359081A1/en
Assigned to INNOBIOSCIENCE, LLC reassignment INNOBIOSCIENCE, LLC Request for Assignment Assignors: Herbal Powers Corporation
Application granted granted Critical
Publication of AU2012359081B2 publication Critical patent/AU2012359081B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012359081A 2011-12-21 2012-12-19 Combination therapy with interferon and andrographolides for multiple sclerosis Active AU2012359081B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578650P 2011-12-21 2011-12-21
US61/578,650 2011-12-21
PCT/US2012/070568 WO2013096423A1 (en) 2011-12-21 2012-12-19 Combination therapy with interferon and andrographolides for multiple sclerosis

Publications (2)

Publication Number Publication Date
AU2012359081A1 AU2012359081A1 (en) 2014-06-05
AU2012359081B2 true AU2012359081B2 (en) 2015-09-17

Family

ID=48669439

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012359081A Active AU2012359081B2 (en) 2011-12-21 2012-12-19 Combination therapy with interferon and andrographolides for multiple sclerosis

Country Status (10)

Country Link
US (1) US9060994B2 (enExample)
EP (1) EP2670406B1 (enExample)
JP (1) JP5936707B2 (enExample)
AU (1) AU2012359081B2 (enExample)
BR (1) BR112014015178A2 (enExample)
CA (1) CA2853779C (enExample)
CL (1) CL2014001663A1 (enExample)
ES (1) ES2554459T3 (enExample)
RU (1) RU2014113967A (enExample)
WO (1) WO2013096423A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6928963B2 (ja) * 2016-06-08 2021-09-01 イノバイオサイエンス， エルエルシー アンドログラホリドが進化型の多発性硬化症を処置する
US11318153B2 (en) 2018-06-25 2022-05-03 Bialpha International Sdn. Bhd. Method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function
CN109824655B (zh) * 2019-04-08 2021-09-24 沈阳药科大学 穿心莲内酯化合物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220764A1 (en) * 2004-04-01 2005-10-06 Schering Aktiengesellschaft Higher-doses of interferon-beta for treatment of multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043027A1 (en) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Treatment of multiple sclerosis with a combination of Interferon and Growth hormone
US6410590B1 (en) * 2000-02-03 2002-06-25 Dr. Reddy's Research Foundation Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
US20050181033A1 (en) 2000-06-29 2005-08-18 Dekker John P.Iii Method for delivering interferons to the intradermal compartment
US20030082138A1 (en) * 2001-09-18 2003-05-01 Chiron Corporation Methods for treating multiple sclerosis
KR20070026398A (ko) 2004-02-03 2007-03-08 우니베르시다드 오스뜨랄 데 칠레 Ｐｐａｒ-감마 수용체의 활성화에 의한 자가면역 질환 및알츠하이머병의 치료에 유용한, 천심련으로부터 추출된랍단 디테르펜을 포함하는 조성물
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220764A1 (en) * 2004-04-01 2005-10-06 Schering Aktiengesellschaft Higher-doses of interferon-beta for treatment of multiple sclerosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PANITCH H. et al, The Lancet, 1987, Vol. 329(8538), pg. 839-895 *

Also Published As

Publication number Publication date
CA2853779A1 (en) 2013-06-27
US9060994B2 (en) 2015-06-23
CA2853779C (en) 2016-04-26
RU2014113967A (ru) 2016-02-10
NZ625051A (en) 2016-07-29
WO2013096423A1 (en) 2013-06-27
ES2554459T3 (es) 2015-12-21
EP2670406B1 (en) 2015-09-02
AU2012359081A1 (en) 2014-06-05
EP2670406A1 (en) 2013-12-11
EP2670406A4 (en) 2014-05-28
JP5936707B2 (ja) 2016-06-22
CL2014001663A1 (es) 2015-02-27
BR112014015178A2 (pt) 2017-06-13
US20140301981A1 (en) 2014-10-09
JP2015500880A (ja) 2015-01-08

Similar Documents

Publication Publication Date Title
US20120328566A9 (en) Estrogen receptor ligand treatment for neurodegenerative diseases
US12310933B2 (en) Treatment of demyelinating disorders
JP2020193206A (ja) 多発性硬化症を治療するためのクラドリビン投薬計画
AU2017203896A1 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
Guo et al. Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis
US20230146896A1 (en) Composition and method for treating alzheimer's disease
AU2012359081B2 (en) Combination therapy with interferon and andrographolides for multiple sclerosis
US20130202555A1 (en) Treatment of multiple sclerosis with masitinib
JP2021165304A (ja) アンドログラホリドが進化型の多発性硬化症を処置する
NZ625051B2 (en) Combination therapy with interferon and andrographolides for multiple sclerosis
KR102177781B1 (ko) 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친, 우르소데옥시콜산 및 비페닐디메틸디카르복실레이트의 복합제제
JPWO2005105089A1 (ja) 精神神経疾患の治療薬
US20220193030A1 (en) Use of ginkgo terpene lactone in preparing drug for preventing and/or treating guillain-barre-strohl syndrome
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
US8664209B2 (en) Daptomycin for multiple sclerosis
RU2786476C2 (ru) Композиция, содержащая антитело против протофибрилл абета и ингибитор бета-секретазы васе1 для лечения болезни альцгеймера
KR20250009742A (ko) 디코토민 B (Dichotomine B)를 유효성분으로 하는 골격근 위축 또는 근감소증 예방, 개선 또는 치료용 약학 조성물, 식품 조성물 또는 사료용 조성물
Class et al. Patent application title: TREATMENT OF MULTIPLE SCLEROSIS WITH MASITINIB Inventors: Alain Moussy (Paris, FR) Alain Moussy (Paris, FR) Jean-Pierre Kinet (Lexington, MA, US) Jean-Pierre Kinet (Lexington, MA, US) Assignees: AB SCIENCE

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: INNOBIOSCIENCE, LLC

Free format text: FORMER APPLICANT(S): HERBAL POWERS CORPORATION

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO GAIN ACCEPTANCE HAS BEEN EXTENDED TO 25 SEP 2015 .

FGA Letters patent sealed or granted (standard patent)